Optimizing Therapeutic Revascularization by Endothelial Cell Transplantation
通过内皮细胞移植优化治疗性血运重建
基本信息
- 批准号:9516109
- 负责人:
- 金额:$ 37.24万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-09-26 至 2019-09-25
- 项目状态:已结题
- 来源:
- 关键词:3D PrintAddressAdultAllogenicAnimal SourcesAnimalsApligrafAttentionAutologousBasement membraneBedsBiologicalBlood VesselsCattleCell LineCell TransplantationCellsChronicClinicalClinical TrialsCollaborationsCollagenCollagen Type ICollagen Type IVCulture MediaCutaneousDermalDermisDevelopmentElastinElderlyEligibility DeterminationEndothelial CellsEngineeringEngraftmentEpidermisEvaluationExposure toExtracellular MatrixFDA approvedFailureFibroblastsFibronectinsFundingGenerationsGoalsGrantHarvestHistologyHumanHuman EngineeringHyaluronic AcidImmune systemImmunodeficient MouseImpaired wound healingImpairmentImplantIn VitroIndividualInfectionInkInstitutesJordanKaryotypeLamininMedicalMembrane ProteinsMorbidity - disease rateMorphologyMusMuscle CellsNatural ProductsNeonatalNewborn InfantPapillaryParentsPerfusionPericytesPreparationPrimary LesionPrintingProductionProteinsRecombinantsRegenerative MedicineResearch Project GrantsRheologyRiskSirolimusSiteSkinSkin SubstitutesSkin UlcerSkin graftSourceSystemTherapeuticThickTissue EngineeringTissuesTransmission Electron MicroscopyUlcerUmbilical Cord BloodVascular Smooth MuscleVascular blood supplyWorkadult stem cellangiogenesisbiophysical techniquesbioprintingcell typeclinical developmentclinical practicecurative treatmentsdiabeticexperimental studyfetal bovine serumhealinghuman tissueimmunocytochemistryinnovationinterstitialkeratinocytemacromoleculemethod developmentnovel strategiesparacrineparent grantperipheral bloodpre-clinicalresponseself assemblysenescencesuccessvascular tissue engineering
项目摘要
7. PROJECT SUMMARY/ABSTRACT
The overall goal of this research project is to develop a vascularized full thickness skin substitute, engraftment
of which can provide a definitive clinical cure of chronic cutaneous ulcers, an unmet medical need. This
application is a competitive Revision to add a specific aim to a funded R01 grant (HL-085416 “Optimizing
Therapeutic Revascularization by Endothelial Cell Transplantation”) submitted in response to RFA-HL-17-029
(Revision Applications for Regenerative Medicine Innovation Projects). The parent R01 grant is focused on
establishing perfusion of tissue engineered grafts through the self-assembly of incorporated human endothelial
cells (EC) into microvessels. We have found that the best source of EC for this purpose is the differentiated
progeny of human endothelial colony forming cells (HECFC), an “adult” stem cell type isolated from neonatal
cord or adult peripheral blood as defined by the terms of this RFA. Over the past six months, Drs. W. Mark
Saltzman and Jordan S. Pober, co-PIs of the parent grant, have established a collaboration with Dr. Pankaj
Karande to apply their approach for microvessel generation to his approach for 3D printing to create a full
thickness human skin substitute. Current FDA-approved skin substitutes have all had only limited clinical
success because they fail to vascularize, and consequently slough over the course of a few weeks. The
vascularized skin substitute produced through this collaboration can potentially address this problem.
However, the skin substitutes that we have generated to date employ bio-inks containing human cells that
have been cultured in fetal bovine serum and use extracellular matrix molecules derived from animal sources.
Similar exposures to animal proteins used in the production of currently approved skin substitutes have further
limited their approved use. The goal of our new specific aim is to develop a vascularized full thickness human
skin substitute through 3D printing made with bio-inks that are composed of human cells that have not been
exposed to animal proteins and extracellular matrix molecules that are either derived from human tissues or
made by recombinant approaches that do not involve exposure to animal proteins. Subaims a and b describe
our approaches to achieve this. Subaim c will involve evaluation of perfusion of the resultant 3D bioprinted skin
graft compared to natural skin and to Apligraf, a currently approved full thickness skin substitute, after
engraftment on immunodeficient mouse hosts. The development of methods for creating a fully humanized and
vascularized full thickness skin equivalent will provide the information needed to develop Good Manufacturing
Practice (GMP) conditions for preparing clinical grade skin substitutes.
7.项目摘要/摘要
这项研究项目的总体目标是开发一种血管化的全层皮肤替代品,植入物
它可以为慢性皮肤溃疡提供明确的临床治疗方法,这是一种尚未得到满足的医疗需求。这
申请是一项竞争性修订,旨在为已资助的R01拨款(HL-085416“优化”)增加一个特定目标
通过内皮细胞移植进行治疗性血管重建术》)
(修订再生医学创新项目申请书)。家长R01奖助金的重点是
通过自组装人内皮细胞建立组织工程移植物的灌流
细胞(EC)转化为微血管。我们发现,用于这一目的的EC的最佳来源是差异化的
人内皮细胞集落形成细胞(HECFC)的后代--一种从新生儿分离的成体干细胞类型
脐带血或成人外周血,如本RFA术语所定义。在过去的六个月里,W.Mark博士
索尔兹曼和乔丹·S·波伯,父母基金的联合私人投资者,已经与潘卡吉博士建立了合作关系
卡兰德将他们的微血管生成方法应用到他的3D打印方法中,以创建完整的
厚厚的人体皮肤替代品。目前FDA批准的皮肤替代品都只有有限的临床应用
成功是因为它们不能血管形成,结果在几周内就崩溃了。这个
通过这种合作生产的血管化皮肤替代品可以潜在地解决这个问题。
然而,到目前为止,我们已经产生的皮肤替代品使用的生物墨水含有人体细胞
已经在胎牛血清中培养,并使用来自动物来源的细胞外基质分子。
与目前批准的皮肤替代品生产中使用的动物蛋白的类似暴露进一步
限制了他们被批准的用途。我们新目标的具体目标是开发一个血管化的全身人
用生物墨水制成的3D打印皮肤替代品,这些墨水是由尚未被
接触动物蛋白和细胞外基质分子,这些分子来自人类组织或
通过不涉及接触动物蛋白的重组方法制成。苏巴姆a和b描述了
我们实现这一目标的方法。Subaim c将评估所得到的3D生物打印皮肤的灌注度。
移植皮肤与天然皮肤和目前批准的全层皮肤替代品Apligraf相比,
在免疫缺陷小鼠宿主上植入。为创造一个完全人性化和
血管化全厚皮肤等价物将提供发展良好制造所需的信息
生产临床级皮肤替代物的实践(GMP)条件。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JORDAN S POBER其他文献
JORDAN S POBER的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JORDAN S POBER', 18)}}的其他基金
Ex Vivo Nanoparticle Drug Delivery Targeted to Human Allograft Endothelium
针对人同种异体移植物内皮的体外纳米颗粒药物输送
- 批准号:
10783379 - 财政年份:2023
- 资助金额:
$ 37.24万 - 项目类别:
Assessment of immunogenicity and antigenicity of different human cell types in natural and 3D-printed allografts
评估天然和 3D 打印同种异体移植物中不同人类细胞类型的免疫原性和抗原性
- 批准号:
10353416 - 财政年份:2021
- 资助金额:
$ 37.24万 - 项目类别:
Assessment of immunogenicity and antigenicity of different human cell types in natural and 3D-printed allografts
评估天然和 3D 打印同种异体移植物中不同人类细胞类型的免疫原性和抗原性
- 批准号:
10194232 - 财政年份:2021
- 资助金额:
$ 37.24万 - 项目类别:
Ex Vivo Nanoparticle Drug Delivery Targeted to Human Renal Allograft Endothelium
针对人肾同种异体移植物内皮的体外纳米颗粒药物输送
- 批准号:
10197784 - 财政年份:2017
- 资助金额:
$ 37.24万 - 项目类别:
Ex Vivo Nanoparticle Drug Delivery Targeted to Human Renal Allograft Endothelium
针对人肾同种异体移植物内皮的体外纳米颗粒药物输送
- 批准号:
10155842 - 财政年份:2017
- 资助金额:
$ 37.24万 - 项目类别:
Targeting Nanoparticles for Drug Delivery to Renal Graft Endothelium during Ex Vivo Normothermic Perfusion
体外常温灌注期间靶向纳米颗粒将药物递送至肾移植物内皮
- 批准号:
9164300 - 财政年份:2016
- 资助金额:
$ 37.24万 - 项目类别:
Bioengineered siRNA/Nanoparticles to Prevent Human Transplant Rejection
生物工程 siRNA/纳米颗粒可防止人体移植排斥
- 批准号:
8693080 - 财政年份:2013
- 资助金额:
$ 37.24万 - 项目类别:
Spatiotemporal Delivery of miRNA Anatgomir for Promoting Vascular Self-Assembly
miRNA Anatgomir 的时空传递促进血管自组装
- 批准号:
8322816 - 财政年份:2011
- 资助金额:
$ 37.24万 - 项目类别:
Controlled Spatiotemporal Delivery of miRNA Anatgomir for Promoting Vascular Self
受控时空递送 miRNA Anatgomir 以促进血管自身
- 批准号:
8138278 - 财政年份:2011
- 资助金额:
$ 37.24万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 37.24万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 37.24万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 37.24万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 37.24万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 37.24万 - 项目类别:
Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 37.24万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 37.24万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 37.24万 - 项目类别:
EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 37.24万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 37.24万 - 项目类别:
Research Grant